Menu Back toV5-S1

14th DIA Japan Annual Meeting 2017


[V5-S1] Future Steps and Challenges for Drug Development Based on National Action Plan on Antimicrobial Resistance (AMR)

    Session Chair(s)
      Junko  Sato, PhD

      Junko Sato, PhD

      • Office Director, Office of International Cooperation
      • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
    Overcoming Antimicrobial-resistant Infection (ARI) has become a global issue. In 2016, the “Ministerial Meeting on Measures on Emerging Infectious Diseases” has announced the National Action Plan on Antimicrobial Resistance (AMR), and as well as a commitment demonstrated in G7 Health Ministers Meeting to solve AMR task. In addition, for a Guideline for the Clinical Evaluation of Antibiotics for ARI, the three regional regulatory agencies (PMDA/FDA/EMA) are cooperating to continue the discussion. This session will discuss future steps based on AMR action plan, about clinical studies in different framework to date, and on international cooperation.
    Speaker(s)
      Yasuhide  Yamada, MSc

      The Japanese Government's Efforts on AMR

      Yasuhide Yamada, MSc

      • Japan
      Wataru  Asakura, PhD

      Therapeutic Drug for Antimicrobial Resistance (AMR) Infections: from Regulatory Standpoint

      Wataru Asakura, PhD

      • Office Director, Office of New Drug IV
      • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
      Akiko  Takase, MPharm

      Challenges in Clinical Development of Drugs for AMR Infections

      Akiko Takase, MPharm

      • Senior Scientist, Regulatory Strategy & Liaison 1, Regulatory Affairs Area
      • MSD K.K., Japan

Contact us

Please contact the DIA Japan office in Tokyo for further information.

Tel: +81-3-6214-0574
Fax: +81-3-3278-1313
Japan@DIAglobal.org
www.diajapan.org